Summary of Study ST001943
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001153. The data can be accessed directly via it's Project DOI: 10.21228/M8P10F This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001943 |
| Study Title | Urinary signature of chronic kidney disease in patients with severe obesity by CE-MS |
| Study Type | Human nephropathy in CKD obese patients |
| Study Summary | Urine metabolomic characterization of severe obese patients with and without chronic kidney disease (CKD) by CE-MS. Analysis was performed in patients before and after bariatric surgery. In the present studio, samples obtained from CKD patients with severe obesity before bariatric surgery will be referred as OD (obese disease). Samples obtained from CKD patients with severe obesity after bariatric surgery will be referred as ODBS (Obese disease bariatric surgery). Patients with severe obesity without CKD will be referenced as O (obese) and after BS, OBS (obese bariatric surgery). In healthy group, when results refer to the first void urine samples, the acronym will be Healthy1V, and the acronym for urine samples collected at 24-hour will be Healthy24h. |
| Institute | University Rey Juan Carlos |
| Department | Basics Science of Health |
| Laboratory | LAFEMEX |
| Last Name | Lanzon |
| First Name | Borja |
| Address | Avenida de Atenas S/N |
| borja.lanzon@urjc.es | |
| Phone | 663692554 |
| Submit Date | 2021-08-19 |
| Num Groups | 6 |
| Total Subjects | 27 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | CE-MS |
| Release Date | 2021-11-04 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Subject:
| Subject ID: | SU002035 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | 53 ± 15 |
| Weight Or Weight Range: | 116 ± 25 |
| Gender: | Male and female |
| Human Inclusion Criteria: | (i) body mass index (BMI)>35kg/m2 plus GFR 30–60ml/min and proteinuria >1 g/24h or GFR>60ml/min and proteinuria >2.5 g/24h despite receiving maximally tolerated doses of renin-angiotensin-aldosterone system (RAAS) blocker and (ii) BMI>40kg/m2 with a GFR>30ml/min and proteinuria >0.5 g/24h despite receiving maximally tolerated doses of RAAS blocker. For the renal function criterion, eGFR was used. The follow-up time was 24 months. |
| Human Exclusion Criteria: | 1) Patients who had participated or were participating in another clinical trial or had taken an experimental drug in the last 28 days. 2) Patients with renal transplantation and/or chronic replacement therapy (hemodialysis and/or peritoneal dialysis). 3) Subjects with poorly controlled blood pressure (SBP > 170 mmHg or DBP > 110 mmHg). 4) Patients with a history of cardiovascular events in the past six months. 5) Patients treated with immunosuppressants. 6) Subjects with a history of renovascular disease, autoimmune diseases, cancer, drug use, or obstructive uropathy. 6) Patients who did not sign the informed consent. 7) Patients who were pregnant or lactating. eGFR was used to establish the renal function criteria. Patients were monitored for 24 months. |
